Stockreport

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal' [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF Follow Summary ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Imm [Read more]